ArticleAnalytical chemistry2025
Sequential versus Simultaneous Quantitative Analysis of Biomarkers in Individual Cells by ICP-MS and Mass Cytometry: A Focus on Immunotherapy.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantification strategies to establish the content of different elements in individual cells are crucial for elucidating any kind of biological conclusion. Technically, this process is hampered when using inductively coupled plasma mass spectrometry (ICP-MS) with nonsimultaneous mass analyzers. This work aims to establish under which set of conditions the sequential and simultaneous detection of different elements in individual cells provides comparable results. Thus, endogenous elements (P and Fe) and Ir as an exogenous cell marker are sequentially measured and quantified using ICP-MS revealing that cell storage and dilution conditions are more critical than cell deposition within the sample introduction device. Under optimized conditions, the interaction of an immunotherapeutic agent (Rituximab) that directs against the B-lymphocyte antigen called cluster of differentiation 20 (CD20) on a B-cell chronic lymphocytic leukemia cell line (MEC-1) is quantified using both single-cell analysis by ICP-MS (SC-ICP-MS) and mass cytometry (CyTOF) after labeling with Lu. Although the obtained values are in good agreement, a general trend is observed with a slight bias toward higher results in SC-ICP-MS versus CyTOF probably ascribed to the automated data treatment system used in CyTOF, discarding double cell events. Both analytical approaches (SC-ICP-MS and CyTOF) showed comparable levels of CD20 expression around 1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.